<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>2059523</identifier>
<setSpec>1130-0108</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Varas Lorenzo, M J</dc:author>
<dc:description xml:lang="en">Ten patients with gastro-pancreatic apudomas were prospectively treated with SMS 201-995 at the dose of 25-50 mg/12 h. subcutaneously before breakfast and dinner during two months. The biological and clinical effects were evaluated, as well its possible antitumoral action. When clinical or biological benefit was ascertained, the treatment was continued uninterruptedly. SMS 201-995 was well tolerated. It allows ambulatory treatment. It reduced hormonal levels in 62% of cases and controlled symptoms in 50%. No antitumoral effects were observed in the majority of patients.</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:date>1991 Feb </dc:date>
<dc:title xml:lang="es">Tratamiento farmacológico de los apudomas gastroenteropancreáticos con el análogo de la somatostatina SMS 201-995 (octreotide).</dc:title>
<dc:title xml:lang="en">[Pharmacological treatment of gastroenteropancreatic apudomas with an analog of somatostatin, SMS 201-995 (octreotide)].</dc:title>
<dc:publisher>Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva</dc:publisher>
</metadata>
</record>
</pubmed-document>
